About this Research Topic
Background: The physiological characteristics of children are different from those of adults, because of immature and not yet fully developed systems. This renders the pharmacokinetics and the pharmacodynamics of drugs more complex in the pediatric population especially in newborns and those delivered preterm that are more prone to oxidative stress than individuals later in life.
Goal: The preclinical and clinical research of new drugs and vaccines for the main pediatric diseases is hampered by ethical and regulatory issues. The translational research and the identification of innovative molecular targets particular for the pediatric population are not yet fully developed. As a consequence, the “off-label” use of drugs and the tentative repositioning of orphan drugs in the clinical setting has recently increased, leading to a poor therapeutic appropriateness. Furthermore, a minority of the entire population is included in clinical studies of drug surveillance. Therefore, the systemic collection of information concerning drugs and vaccines most frequently associated with the onset of Adverse Drug Reactions (ADR) is of paramount importance. The goal is to provide a new, challenging scenario for the therapeutic needs in the pediatric population.
Scope and information for Author: This thematic issue will focus on these aspects with the aim to foster a more rationale and safe use of the drugs in the pediatric population. Papers dealing with preclinical and clinical research and reviews on the main pharmacological approaches of the main pediatric diseases will be suitable for publication.
Goal: The preclinical and clinical research of new drugs and vaccines for the main pediatric diseases is hampered by ethical and regulatory issues. The translational research and the identification of innovative molecular targets particular for the pediatric population are not yet fully developed. As a consequence, the “off-label” use of drugs and the tentative repositioning of orphan drugs in the clinical setting has recently increased, leading to a poor therapeutic appropriateness. Furthermore, a minority of the entire population is included in clinical studies of drug surveillance. Therefore, the systemic collection of information concerning drugs and vaccines most frequently associated with the onset of Adverse Drug Reactions (ADR) is of paramount importance. The goal is to provide a new, challenging scenario for the therapeutic needs in the pediatric population.
Scope and information for Author: This thematic issue will focus on these aspects with the aim to foster a more rationale and safe use of the drugs in the pediatric population. Papers dealing with preclinical and clinical research and reviews on the main pharmacological approaches of the main pediatric diseases will be suitable for publication.
Keywords: Pediatric Population, Efficacy and Safety, Translational Research, Preclinical and Clinical studies, Drugs and Vaccines, Prescriptive appropriateness, Off-label drug use, Pharmacovigilance
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
